Sequana Medical Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Ian Crosbie

Chief executive officer

€440.6k

Total compensation

CEO salary percentage	96.5%
CEO tenure	8.3yrs
CEO ownership	n/a
Management average tenure	5.1yrs
Board average tenure	4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ian Crosbie's remuneration changed compared to Sequana Medical's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€441k	€425k	-€33m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€32m
Mar 31 2023	n/a	n/a	-€32m
Dec 31 2022	€464k	€449k	-€31m
Sep 30 2022	n/a	n/a	-€29m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€25m
Dec 31 2021	€417k	n/a	-€24m

Compensation vs Market: Ian 's total compensation ($USD478.26K) is about average for companies of similar size in the German market ($USD385.89K).

Compensation vs Earnings: Ian 's compensation has been consistent with company performance over the past year.

CEO

Ian Crosbie

8.3yrs

Tenure

€440,569

Compensation

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV since 2016 and serves as its Director since 2019. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ian Crosbie	CEO & Executive Director	8.3yrs	€440.57k	no data
Kirsten Van Bockstaele	Chief Financial Officer	no data	€355.98k	no data
Lies Vanneste	Director of Investor Relations	5.1yrs	no data	no data
Martijn Blom	Chief Commercial Officer	no data	no data	no data
Oliver Godje	Chief Medical Officer	4yrs	no data	no data

5.1yrs

Average Tenure

49yo

Average Age

Experienced Management: 2SE's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ian Crosbie	CEO & Executive Director	5.3yrs	€440.57k	no data
Erik Amble	Observer	1.8yrs	no data	no data
Wim Ottevaere	Independent Non-Executive Director	5.3yrs	€52.50k	0.069% € 36.2k
James Udelson	Heart Failure Scientific Advisor	3.6yrs	no data	no data
Rudy Dekeyser	Non-Executive Director	no data	no data	no data
Maria Costanzo	Scientific Advisor	4.7yrs	no data	no data
Pierre Chauvineau	Independent Chairman	5.3yrs	€71.50k	0.025% € 13.2k
Javed Butler	Scientific Advisor	4.7yrs	no data	no data
Jeffrey Testani	Scientific Advisor	4.7yrs	no data	no data
W.H. Tang	Scientific Advisor	4.7yrs	no data	no data
Jackie Fielding	Independent Non-Executive Director	2.7yrs	€49.00k	no data
G. Felker	Heart Failure Scientific Advisor	3.6yrs	no data	no data

4.7yrs

Average Tenure

64yo

Average Age

Experienced Board: 2SE's board of directors are considered experienced (4.7 years average tenure).

Sequana Medical Management

Management criteria checks 4/4

Key information

Recent management updates

Sequana Medical NV, Annual General Meeting, May 23, 2024

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

High number of new directors

Sequana Medical NV Announces Board Changes

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Recent updates

New major risk - Shareholder dilution

Full year 2023 earnings released: €1.22 loss per share (vs €1.35 loss in FY 2022)

Sequana Medical NV to Report First Half, 2024 Results on Sep 19, 2024

Sequana Medical NV to Report First Half, 2024 Results on Sep 12, 2024

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure

No longer forecast to breakeven

New minor risk - Financial data availability

Sequana Medical NV has filed a Follow-on Equity Offering in the amount of €12 million.

New minor risk - Profitability

New major risk - Financial position

Sequana Medical NV, Annual General Meeting, May 23, 2024

Forecast to breakeven in 2026

New minor risk - Market cap size

Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

New major risk - Share price stability

Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome

Forecast to breakeven in 2024

First half 2023 earnings released: €0.65 loss per share (vs €0.68 loss in 1H 2022)

New major risk - Financial position

Sequana Medical NV to Report Q2, 2023 Results on Sep 14, 2023

Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure

Forecast to breakeven in 2024

Sequana Medical NV Announces Completion of 1,000th Alfapump Implant

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

Full year 2022 earnings released: €1.35 loss per share (vs €1.30 loss in FY 2021)

Full year 2022 earnings released: €1.35 loss per share (vs €1.30 loss in FY 2021)

Sequana Medical Announces Successful Completion of Pre-Clinical Studies with its Second-Generation DSR Product for Congestive Heart Failure

Sequana Medical NV Announces Positive Top-Line Results from SAHARA Ph. 2a Study of DSR 1.0 in Diuretic-Resistant Heart Failure Patients with Persistent Congestion and First Patient Dosed Successfully with DSR 2.0 in YUKON

High number of new directors

Sequana Medical NV Announces Positive Top-Line Results from the North American Pivotal POSEIDON study of the alfapump

First half 2022 earnings released: €0.68 loss per share (vs €0.66 loss in 1H 2021)

Sequana Medical NV to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Sequana Medical NV Announces Board Changes

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR, Reports Disease-Modifying Profile for Short Term DSR

High number of new and inexperienced directors

Full year 2021 earnings released: €1.30 loss per share (vs €1.25 loss in FY 2020)

Sequana Medical Announces the Completion of Alfapump Implantations in Poseidon, the North American Pivotal Alfapump Study

Sequana Medical NV Receives Certification Under Mdr, the New European Medical Device Regulation

Sequana Medical NV Announces the Completion of Patient Enrolment in Poseidon, the North American Pivotal Alfapump Study

First half 2021 earnings released: €0.66 loss per share (vs €0.62 loss in 1H 2020)

Independent Non-Executive Director Jason Hannon has left the company

Sequana Medical’s Results from RED DESERT Alfapump DSR® Study Presented as One of the Highlights At Heart Failure 2021 Online Congress

Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019)

Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON)

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age